GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Ending Cash Position

Mesoblast (Mesoblast) Ending Cash Position : $77.55 Mil (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Ending Cash Position?

Mesoblast's Ending Cash Position for the quarter that ended in Dec. 2023 was $77.55 Mil.

Mesoblast's quarterly Ending Cash Position declined from Jun. 2023 ($71.32 Mil) to Sep. 2023 ($53.18 Mil) but then increased from Sep. 2023 ($53.18 Mil) to Dec. 2023 ($77.55 Mil).

Mesoblast's annual Ending Cash Position declined from Jun. 2021 ($136.88 Mil) to Jun. 2022 ($60.45 Mil) but then increased from Jun. 2022 ($60.45 Mil) to Jun. 2023 ($71.32 Mil).

Mesoblast Ending Cash Position Historical Data

The historical data trend for Mesoblast's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Ending Cash Position Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.43 129.33 136.88 60.45 71.32

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.62 48.80 71.32 53.18 77.55

Mesoblast Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Mesoblast's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=60.447+10.871
=71.32

Mesoblast's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=40.849+36.705
=77.55

Mesoblast Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Mesoblast's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Ending Cash Position
Comparable Companies
ASX:OPT ASX:IMM ASX:CUV ASX:CU6 ASX:BOT ASX:IMU ASX:PYC ASX:RAC ASX:DXB ASX:PIQ OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MEOBF:USA LWB:Germany MSB:Australia
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Website
https://www.mesoblast.com
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.